Pemetrexed dipotassium heptahydrate

Pemetrexed dipotassium heptahydrate is a chemotherapy drug used mainly to treat malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC). It works as a folate analog metabolic inhibitor, disrupting folate-dependent processes essential for cell replication by inhibiting enzymes involved in the biosynthesis of thymidine and purine nucleotides. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Axtle (TN), L-Glutamic acid, N-[4-[2-(2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo[2, 3-d]pyrimidin-5-yl)ethyl]benzoyl]-, potassium salt and hydrate (1:2:7). Its PubChem CID is 136238656.

CAS No 2668267-29-4
Molecular Formula C20H33K2N5O13
Molecular Weight 629.7 g/mol
Synonyms dipotassium;(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate;heptahydrate

Frequently Asked Questions